Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Trial Profile

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms IISP-Raltegravir
  • Most Recent Events

    • 16 Feb 2017 Results (n=37) assessing effect of switching from protease and non-nucleotide reverse transcriptase inhibitors-based regimens to raltegravir-based regimens on biomarkers of liver steatosis and metabolic syndrome in women, presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 06 Mar 2013 Biomarker results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 20 Jul 2011 Results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top